Knockdown of CLN5 inhibits the tumorigenic properties of glioblastoma cells via the Akt/mTOR signaling pathway

Xing,Jiexia; Li,Ying; Zhao,Huilan

doi:10.3892/ol.2021.12648

Knockdown of CLN5 inhibits the tumorigenic properties of glioblastoma cells via the Akt/mTOR signaling pathway

Authors:
- Jiexia Xing
- Ying Li
- Huilan Zhao
View Affiliations

Affiliations: Department of Neurology, Shandong University of Qilu Hospital, Jinan, Shandong 250012, P.R. China, Department of Critical Medicine, The Third People's Hospital of Heze, Heze, Shandong 274000, P.R. China, Department of Geriatrics, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250011, P.R. China
Published online on: March 17, 2021 https://doi.org/10.3892/ol.2021.12648
Article Number: 387
Copyright: © Xing et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gliomas are highly malignant tumors with a rapid progression and poor prognosis. The present study investigated the cellular effects of CLN5‑knockdown in the glioblastoma (GBM) U251 and U87MG cell lines. The Cell Counting Kit‑8 and colony formation assays indicated that CLN5‑knockdown inhibited the proliferation of GBM cells. Additionally, the results of the Transwell and scratch assays revealed that CLN5‑knockdown significantly inhibited migration and invasion, and the flow cytometry analysis confirmed that apoptosis was promoted. Knockdown of CLN5 downregulated the expression levels of MMP‑2, Bcl‑2, cyclin D1, CDK4 and CDK6, and upregulated the expression levels of Bax and activated caspase‑9. Additionally, it blocked GBM cells in the G1‑phase and induced early apoptosis. Knockdown of CLN5 inhibited the activation of the Akt and mTOR signaling pathways in GBM by decreasing the levels of phosphorylated (p)‑Akt and p‑mTOR. The present data suggested that downregulation of CLN5 may be a potential treatment option for GBM. Knockdown of CLN5 inhibited the development of GBM via the inhibition of the Akt and mTOR signaling pathways.

View Figures

View References

1	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
2	Brandsma D, Stalpers L, Taal W, Sminia P and van den Bent MJ: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 9:453–461. 2008. View Article : Google Scholar : PubMed/NCBI
3	Davis FG, Freels S, Grutsch J, Barlas S and Brem S: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg. 88:1–10. 2008. View Article : Google Scholar
4	Penas-Prado M and Gilbert MR: Molecularly targeted therapies for malignant gliomas: Advances and challenges. Expert Rev Anticancer Ther. 7:641–661. 2007. View Article : Google Scholar : PubMed/NCBI
5	Tachon G, Masliantsev K, Rivet P, Petropoulos C, Godet J, Milin S, Wager M, Guichet PO and Karayan-Tapon L: Prognostic significance of MEOX2 in gliomas. Mod Pathol. 32:774–786. 2019. View Article : Google Scholar : PubMed/NCBI
6	Komori T, Sasaki H and Yoshida K: Revised WHO classification of tumours of the central nervous system: Summary of the revision and perspective. No Shinkei Geka. 44:625–635. 2016.(In Japanese). PubMed/NCBI
7	Wolf A, Agnihotri S and Guha A: Erratum: Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget. 9:348552018. View Article : Google Scholar : PubMed/NCBI
8	Khosla D: Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann Transl Med. 4:542016.PubMed/NCBI
9	Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453. 2007. View Article : Google Scholar : PubMed/NCBI
10	Xu P, Yang J, Liu J, Yang X, Liao J, Yuan F, Xu Y, Liu B and Chen Q: Identification of glioblastoma gene prognosis modules based on weighted gene co-expression network analysis. BMC Med Genomics. 11:962018. View Article : Google Scholar : PubMed/NCBI
11	Gao XF, He HQ, Zhu XB, Xie SL and Cao Y: lncRNA SNHG20 promotes tumorigenesis and cancer stemness in glioblastoma via activating PI3K/Akt/mTOR signaling pathway. Neoplasma. 66:532–542. 2019. View Article : Google Scholar : PubMed/NCBI
12	Hudson K, Hancox UJ, Trigwell C, McEwen R, Polanska UM, Nikolaou M, Morentin Gutierrez P, Avivar-Valderas A, Delpuech O, Dudley P, et al: Intermittent high dose scheduling of AZD8835, a novel selective inhibitor of PI3Kα and PI3Kδ, demonstrates treatment strategies for PIK3CA-dependent breast cancers. Mol Cancer Ther. 15:877–889. 2016. View Article : Google Scholar : PubMed/NCBI
13	Yu JZ, Ying Y, Liu Y, Sun CB, Dai C, Zhao S, Tian SZ, Peng J, Han NP, Yuan JL, et al: Antifibrotic action of Yifei Sanjie formula enhanced autophagy via PI3K-AKT-mTOR signaling pathway in mouse model of pulmonary fibrosis. Biomed Pharmacother. 118:1092932019. View Article : Google Scholar : PubMed/NCBI
14	Mitchison HM and Mole SE: Neurodegenerative disease: The neuronal ceroid lipofuscinoses (Batten disease). Curr Opin Neurol. 14:795–803. 2001. View Article : Google Scholar : PubMed/NCBI
15	Savukoski M, Klockars T, Holmberg V, Santavuori P and Peltonen L: CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis. Nat Genet. 19:286–288. 1998. View Article : Google Scholar : PubMed/NCBI
16	Vesa J, Chin MH, Oelgeschläger K, Isosomppi J, DellAngelica EC, Jalanko A and Peltonen L: Neuronal Ceroid Lipofuscinoses Are Connected at Molecular Level: Interaction of CLN5 Protein with CLN2 and CLN3. Mol Biol Cell. 13:2410–2420. 2002. View Article : Google Scholar : PubMed/NCBI
17	Lebrun AH, Storch S, Rüschendorf F, Schmiedt ML, Kyttälä A, Mole SE, Kitzmüller C, Saar K, Mewasingh LD, Boda V, et al: Retention of lysosomal protein CLN5 in the endoplasmic reticulum causes neuronal ceroid lipofuscinosis in Asian sibship. Hum Mutat. 30:E651–E61. 2009. View Article : Google Scholar : PubMed/NCBI
18	Bouhamdani N, Comeau D, Cormier K and Turcotte S: STF-62247 accumulates in lysosomes and blocks late stages of autophagy to selectively target von Hippel-Lindau-inactivated cells. Am J Physiol Cell Physio. 316:C605–C620. 2019. View Article : Google Scholar
19	Jia R and Bonifacino JS: Lysosome positioning influences mTORC2 and AKT signaling. Mol Cell. 75:26–38.e3. 2019. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Tang Z, Li C, Kang B, Ge G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
22	Bahadur S, Sahu AK, Baghel P and Saha S: Current promising treatment strategy for glioblastoma multiform: A review. Oncol Rev. 13:417:2019. View Article : Google Scholar : PubMed/NCBI
23	Yilmaz M, Christofori G and Lehembre F: Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med. 13:535–541. 2007. View Article : Google Scholar : PubMed/NCBI
24	Schrump DS, Chen A and Consoli U: Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene The. 3:131–135. 1996.
25	Stewart CJ and Crook ML: CD147 (EMMPRIN) and matrix metalloproteinase-2 expression in uterine endometrioid adenocarcinoma. Pathol Res Pract. 207:30–36. 2011. View Article : Google Scholar : PubMed/NCBI
26	Hoshyar R, Bathaie SZ and Sadeghizadeh M: Crocin Triggers the apoptosis through increasing the Bax/Bcl-2 ratio and caspase activation in human gastric adenocarcinoma, AGS, cells. DNA Cell Biol. 32:50–57. 2013. View Article : Google Scholar : PubMed/NCBI
27	Viallard JF, Lacombe F, Belloc F, Pellegrin JL and Reiffers J: Molecular mechanisms controlling the cell cycle: Fundamental aspects and implications for oncology. Cancer Radiother. 5:109–129. 2001.(In French). View Article : Google Scholar : PubMed/NCBI
28	Yang HL, Kuo YH, Tsai CT, Huang YT, Chen SC, Chang HW, Lin E, Lin WH and Hseu YC: Anti-metastatic activities of Antrodia camphorata against human breast cancer cells mediated through suppression of the MAPK signaling pathway. Food Chem Toxicol. 49:290–298. 2011. View Article : Google Scholar : PubMed/NCBI